BioCentury | Apr 15, 2013
Clinical News

Remune inactivated data

...reproduction. Details of the open-label trial will be published in the Journal of Human Virology. The Immune Response Corp....
BioCentury | Apr 15, 2013
Clinical News

Immune Response regulatory update

...human cell line engineered to express one or more antigens and one or more cytokines. The Immune Response Corp....
BioCentury | Apr 15, 2013
Clinical News

IR501 data

...of at least 20 percent from baseline, and improvements in three of five other criteria. The Immune Response Corp....
BioCentury | Mar 23, 2009
Finance

Ebb & Flow

...readers of the white paper may have raised their eyebrows upon seeing the bankruptcy of Orchestra Therapeutics Inc....
...example of the biotech sector's woes brought on by the current economic climate. Orchestra (formerly The Immune Response Corp....
BioCentury | Oct 20, 2008
Company News

Orchestra Therapeutics autoimmune news

...Orchestra filed for Chapter 7 bankruptcy. Orchestra (formerly The Immune Response Corp. ) restructured and reduced headcount in April...
...in Phase IIb testing to treat relapsing-remitting multiple sclerosis (RRMS) (see BioCentury, April 9, 2007). Orchestra Therapeutics Inc....
BioCentury | May 12, 2008
Company News

Artes management update

...San Diego, Calif. Business: Dermatology Hired: Michael Green as CFO, formerly CFO and COO of Orchestra Therapeutics Inc....
BioCentury | Jul 23, 2007
Clinical News

IR103: Development discontinued

...company said it would seek strategic alternatives for its HIV program (see BioCentury, April 9). Orchestra Therapeutics Inc....
BioCentury | Jul 23, 2007
Clinical News

Remune HIV-1 immunogen: Development discontinued

...company said it would seek strategic alternatives for its HIV program (see BioCentury, April 9). Orchestra Therapeutics Inc....
BioCentury | Apr 9, 2007
Company News

Immune Response autoimmune news

...loss of $13.3 million. IMRP also will change its name to Orchestra Therapeutics Inc. effective April 16. The Immune Response Corp....
BioCentury | Mar 12, 2007
Clinical News

NeuroVax: Phase IIb started

...IMRP started a placebo-controlled, double-blind, U.S. and European Phase IIb trial in 200 patients. The Immune Response Corp. (IMRP...
Items per page:
1 - 10 of 243
BioCentury | Apr 15, 2013
Clinical News

Remune inactivated data

...reproduction. Details of the open-label trial will be published in the Journal of Human Virology. The Immune Response Corp....
BioCentury | Apr 15, 2013
Clinical News

Immune Response regulatory update

...human cell line engineered to express one or more antigens and one or more cytokines. The Immune Response Corp....
BioCentury | Apr 15, 2013
Clinical News

IR501 data

...of at least 20 percent from baseline, and improvements in three of five other criteria. The Immune Response Corp....
BioCentury | Mar 23, 2009
Finance

Ebb & Flow

...readers of the white paper may have raised their eyebrows upon seeing the bankruptcy of Orchestra Therapeutics Inc....
...example of the biotech sector's woes brought on by the current economic climate. Orchestra (formerly The Immune Response Corp....
BioCentury | Oct 20, 2008
Company News

Orchestra Therapeutics autoimmune news

...Orchestra filed for Chapter 7 bankruptcy. Orchestra (formerly The Immune Response Corp. ) restructured and reduced headcount in April...
...in Phase IIb testing to treat relapsing-remitting multiple sclerosis (RRMS) (see BioCentury, April 9, 2007). Orchestra Therapeutics Inc....
BioCentury | May 12, 2008
Company News

Artes management update

...San Diego, Calif. Business: Dermatology Hired: Michael Green as CFO, formerly CFO and COO of Orchestra Therapeutics Inc....
BioCentury | Jul 23, 2007
Clinical News

IR103: Development discontinued

...company said it would seek strategic alternatives for its HIV program (see BioCentury, April 9). Orchestra Therapeutics Inc....
BioCentury | Jul 23, 2007
Clinical News

Remune HIV-1 immunogen: Development discontinued

...company said it would seek strategic alternatives for its HIV program (see BioCentury, April 9). Orchestra Therapeutics Inc....
BioCentury | Apr 9, 2007
Company News

Immune Response autoimmune news

...loss of $13.3 million. IMRP also will change its name to Orchestra Therapeutics Inc. effective April 16. The Immune Response Corp....
BioCentury | Mar 12, 2007
Clinical News

NeuroVax: Phase IIb started

...IMRP started a placebo-controlled, double-blind, U.S. and European Phase IIb trial in 200 patients. The Immune Response Corp. (IMRP...
Items per page:
1 - 10 of 243